Aarhus, Denmark, 25 March 2025 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces ...

NMD Pharma ApS has discovered chloride channel protein 1 (CLCN1; ClC-1) channel blockers reported to be useful for the treatment of myasthenia gravis, Lambert-Eaton syndrome, critical illness myopathy ...

Chloride channels, particularly those of the CLC family, are vital for cellular homeostasis by facilitating the exchange of chloride ions and protons across membranes. These transport proteins govern ...

Skeletal muscle channelopathies and myotonic disorders constitute a heterogeneous group of neuromuscular conditions caused by mutations that impair the function of ion channels, including sodium and ...

NMD Pharma ApS has described chloride channel protein 1 (CLCN1; ClC-1) channel blockers reported to be useful for the treatment of myasthenia gravis, Lambert-Eaton syndrome, critical illness myopathy, ...